Icosavax is a biopharmaceutical company developing vaccines against infectious diseases, primarily focusing on life-threatening respiratory illnesses like RSV, hMPV, and SARS-CoV-2 using computationally designed virus-like particle (VLP) platform technology.[1][2][3] Its lead candidate, IVX-A12, is a combination RSV/hMPV vaccine that received FDA Fast Track designation, targeting older adults and those with chronic conditions, with Phase 1 trials initiated in 2022 and topline results expected mid-2023, followed by Phase 2 in late 2023.[1] The company serves vulnerable populations by addressing unmet needs in respiratory vaccine protection, leveraging VLPs for multivalent, durable immune responses without strong adjuvants.[1][3]
Icosavax's growth includes a $51 million Series A in 2019, a 2021 IPO filing amid biotech momentum, and a planned $1.1 billion acquisition by AstraZeneca announced in late 2023, positioning IVX-A12 as a Phase III-ready asset.[3][5][6]
Icosavax was formed in 2017 (with some sources noting 2018) as a spinout from the University of Washington's Institute for Protein Design (IPD), exclusively licensing breakthrough computationally designed self-assembling VLP technology invented there.[1][2][6] Scientific co-founders Neil King, Ph.D., who led early research on protein self-assembly in David Baker's lab, and David Baker, IPD head, drove the vision for vaccines mimicking natural viruses to elicit superior immune responses.[3][5][6] CEO Adam Simpson, with prior experience leading IPD spinout PvP Biologics (sold to Takeda), joined to advance commercialization.[5]
The idea emerged from IPD research published in high-impact journals like *Cell* and *Science*, incorporating elements like the stabilized prefusion F antigen (DS-Cav1) licensed from NIH/NIAID.[3] Early traction came via preclinical studies showing high neutralizing antibodies, a Bill & Melinda Gates Foundation grant for COVID-19 trials, and Phase 1/2 initiation in 2021.[1][5]
Icosavax rides the wave of computational protein design and mRNA/biotech vaccine advances post-COVID, enabling precise, virus-mimicking nanoparticles for hard-to-target respiratory pathogens lacking approved vaccines.[5][6] Timing aligns with surging demand for older-adult protections amid aging populations and RSV/hMPV burdens, amplified by pandemic-era investor enthusiasm (49 biotech IPOs by mid-2021 raising $8.8B).[5] Market forces like FDA Fast Track and grants (e.g., Gates Foundation) favor it, while its IPD roots influence the ecosystem by validating de novo protein tech—seen in SKYCovione and AstraZeneca's $1.1B buyout, accelerating Phase III for IVX-A12.[1][6]
Post-2023 AstraZeneca acquisition, Icosavax's VLP platform integrates into a major pipeline, fast-tracking IVX-A12 to Phase III for RSV/hMPV approval, potentially first-in-class by 2026-2027 amid rising respiratory combo vaccine needs.[1][6] Trends like AI-driven design, pan-respiratory vaccines, and global infectious disease prevention will shape it, evolving its influence from UW spinout to cornerstone of next-gen prophylactics. This builds on its core mission: computationally precise vaccines transforming public health.
Icosavax has raised $151.0M in total across 2 funding rounds.
Icosavax's investors include MPM Capital, Qiming Venture Partners USA, RA Capital, Vida Ventures.
Icosavax has raised $151.0M across 2 funding rounds. Most recently, it raised $100.0M Series B in April 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2021 | $100.0M Series B | MPM Capital, Qiming Venture Partners USA, RA Capital, Vida Ventures | |
| Oct 1, 2019 | $51.0M Series A | Qiming Venture Partners USA, RA Capital |